Literature DB >> 15128744

The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.

John B Walker1, Laszlo Bajzar.   

Abstract

Activated thrombin-activable fibrinolysis inhibitor (TAFIa) is intrinsically unstable, a property that complicates the study of its role in regulating fibrinolysis. To investigate the effect of basic carboxypeptidases on fibrinolysis under conditions of constant carboxypeptidase activity, we employed pancreatic carboxypeptidase B (CPB), a homologous, stable basic carboxypeptidase, as a surrogate for TAFIa. Clots formed from TAFI-depleted plasma or from purified components were supplemented with tissue-type plasminogen activator and either CPB or TAFIa. The clot lysis data indicate that the down-regulation of fibrinolysis mediated by basic carboxypeptidases involves a threshold mechanism. At carboxypeptidase concentrations above the threshold, plasminogen activation is maintained in a fully down-regulated state; experiments in plasma showed that fibrinolysis is essentially halted by saturating concentrations of TAFIa and that fibrinolysis can be prolonged more than 45-fold by a stable carboxypeptidase. The threshold carboxypeptidase concentration was dependent on tissue-type plasminogen activator and antiplasmin concentrations, indicating that the threshold is determined by the steady-state plasmin concentration. Although obvious with CPB, the threshold was masked by the intrinsic instability of TAFIa and became apparent only when the effect of TAFIa was investigated over the picomolar concentration range. Because of the threshold effect and the instability of TAFIa, exponential increases in TAFIa concentration generate linear increases in lysis time. A model relating lysis time to TAFIa concentration, TAFIa half-life, and the threshold concentration of TAFIa is provided. The threshold effect has potentially important implications regarding the role of TAFIa and the regulation of clot lysis in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15128744     DOI: 10.1074/jbc.M401027200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis.

Authors:  Xianzhen Hu; Rick A Wetsel; Theresa N Ramos; Stacey L Mueller-Ortiz; Trenton R Schoeb; Scott R Barnum
Journal:  Immunobiology       Date:  2013-08-23       Impact factor: 3.144

2.  Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.

Authors:  Tanya M Binette; Fletcher B Taylor; Glenn Peer; Laszlo Bajzar
Journal:  Blood       Date:  2007-07-20       Impact factor: 22.113

3.  Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.

Authors:  Jonathan H Foley; Paula Kim; Michael E Nesheim
Journal:  J Biol Chem       Date:  2008-02-05       Impact factor: 5.157

4.  Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.

Authors:  Laurent O Mosnier
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

5.  Kinetic model facilitates analysis of fibrin generation and its modulation by clotting factors: implications for hemostasis-enhancing therapies.

Authors:  Alexander Y Mitrophanov; Alisa S Wolberg; Jaques Reifman
Journal:  Mol Biosyst       Date:  2014-07-29

6.  Kinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sites.

Authors:  Jonathan H Foley; Paul F Cook; Michael E Nesheim
Journal:  J Biol Chem       Date:  2011-04-05       Impact factor: 5.157

Review 7.  An unmet clinical need: The history of thrombus imaging.

Authors:  Gregory M Lanza; Grace Cui; Anne H Schmieder; Huiying Zhang; John S Allen; Michael J Scott; Todd Williams; Xiaoxia Yang
Journal:  J Nucl Cardiol       Date:  2017-06-12       Impact factor: 5.952

8.  Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation.

Authors:  Masahiro Ieko; Mika Yoshida; Sumiyoshi Naito; Toru Nakabayashi; Kaoru Kanazawa; Kazuhiro Mizukami; Masaya Mukai; Tatsuya Atsumi; Takao Koike
Journal:  Int J Hematol       Date:  2010-05-21       Impact factor: 2.490

Review 9.  Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Authors:  J L Willemse; E Heylen; M E Nesheim; D F Hendriks
Journal:  J Thromb Haemost       Date:  2009-08-28       Impact factor: 5.824

10.  Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin.

Authors:  András Kovács; László Szabó; Colin Longstaff; Kiril Tenekedjiev; Raymund Machovich; Krasimir Kolev
Journal:  Thromb Res       Date:  2013-09-21       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.